- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and ...

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S.- - Ann & Robert H. Lurie Children's ...

Abeona Therapeutics has received FDA approval for ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...

Skin grafts genetically engineered from a patient’s own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...

This week marked the first time a patient with recessive dystrophic epidermolysis bullosa (RDEB) received prademagene zamikeracel (pz-cel, Zevaskyn), a first-of-its-kind autologous gene therapy to ...